Status: Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.
Participants needed: 23
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Jul 25, 2024Locations: 1
Eligibility criteria
18 years of age or older. [+8]
Combined with other malignancy(except for clinically cured in situ cervix carcin... [+23]